Study of GS-5319 in Adults With Solid Tumors

2025-522397-36-00 Protocol GS-US-707-7297 Human pharmacology (Phase I) - First administration to humans Authorised, recruiting

Start 18 Dec 2025 · Status Authorised, recruiting · 1 EU/EEA countries · 3 sites · Protocol GS-US-707-7297

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruiting
Participants planned 178
Countries 1
Sites 3

Advanced solid tumors

Key facts

Sponsor
Gilead Sciences Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
18 Dec 2025 → ongoing
Decision date (initial)
2025-11-24
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced solid tumors

VersionLevelCodeTermSystem organ class
21.1 PT 10028997 Neoplasm malignant 100000004864
27.1 PT 10028980 Neoplasm 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Gilead Sciences Inc.

Sponsor organisation
Gilead Sciences Inc.
Address
333 Lakeside Drive
City
Foster City
Postcode
94404-1147
Country
United States

Scientific contact point

Organisation
Gilead Sciences Inc.
Contact name
EU CT Support

Public contact point

Organisation
Gilead Sciences Inc.
Contact name
EU CT Support

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Authorised, recruiting 35 3
Rest of world
Canada, Korea, Republic of, United Kingdom, United States
143

Investigational sites

Spain

3 sites · Authorised, recruiting
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Oncology (VHIO), Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Start Madrid - FJD, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario Hm Sanchinarro
Start - Centro Integral Oncológico Clara Campal, Calle Ona 10, 28050, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2025-12-18

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-07-31 Spain Acceptable with conditions
2025-11-18
2025-11-24
2 SUBSTANTIAL MODIFICATION SM-1 2026-01-22 Spain Acceptable with conditions 2026-01-28